Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Is the subcutaneous route an alternative for administering ertapenem to older patients? PHACINERTA study.

Roubaud Baudron C, Legeron R, Ollivier J, Bonnet F, Greib C, Guerville F, Cazanave C, Kobeh D, Cressot V, Moneger N, Videau MN, Thiel E, Foucaud C, Lafargue A, de Thezy A, Durrieu J, Bourdel Marchasson I, Pinganaud G, Breilh D.

J Antimicrob Chemother. 2019 Dec 1;74(12):3546-3554. doi: 10.1093/jac/dkz385.

PMID:
31730164
2.

Are Standard Dosing Regimens of Ceftriaxone Adapted for Critically Ill Patients with Augmented Creatinine Clearance?

Ollivier J, Carrié C, d'Houdain N, Djabarouti S, Petit L, Xuereb F, Legeron R, Biais M, Breilh D.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02134-18. doi: 10.1128/AAC.02134-18. Print 2019 Mar.

3.

Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion.

Carrié C, Legeron R, Petit L, Ollivier J, Cottenceau V, d'Houdain N, Boyer P, Lafitte M, Xuereb F, Sztark F, Breilh D, Biais M.

J Crit Care. 2018 Dec;48:66-71. doi: 10.1016/j.jcrc.2018.08.026. Epub 2018 Aug 23.

PMID:
30172963
4.

Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of β-lactams administered by continuous infusion: a prospective observational study.

Carrié C, Petit L, d'Houdain N, Sauvage N, Cottenceau V, Lafitte M, Foumenteze C, Hisz Q, Menu D, Legeron R, Breilh D, Sztark F.

Int J Antimicrob Agents. 2018 Mar;51(3):443-449. doi: 10.1016/j.ijantimicag.2017.11.013. Epub 2017 Nov 24.

PMID:
29180280
5.

A new reliable, transposable and cost-effective assay for absolute quantification of total plasmatic bevacizumab by LC-MS/MS in human plasma comparing two internal standard calibration approaches.

Legeron R, Xuereb F, Chaignepain S, Gadeau AP, Claverol S, Dupuy JW, Djabarouti S, Couffinhal T, Schmitter JM, Breilh D.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Dec 1;1070:43-53. doi: 10.1016/j.jchromb.2017.10.042. Epub 2017 Oct 23.

PMID:
29111437
6.

Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under- and Overdosing.

Jung B, Mahul M, Breilh D, Legeron R, Signe J, Jean-Pierre H, Uhlemann AC, Molinari N, Jaber S.

Crit Care Med. 2017 May;45(5):e470-e478. doi: 10.1097/CCM.0000000000002287.

PMID:
28240688
7.

Pre-dose plasma concentration monitoring of mycophenolate mofetil in patients with autoimmune diseases.

Streicher C, Djabarouti S, Xuereb F, Lazaro E, Legeron R, Bouchet S, Greib C, Breilh D, Pellegrin JL, Viallard JF.

Br J Clin Pharmacol. 2014 Dec;78(6):1419-25. doi: 10.1111/bcp.12462.

8.

Chemical stability of azacitidine suspensions for injection after cold-chain reconstitution of powder and storage.

Legeron R, Xuereb F, Djabarouti S, Saux MC, Breilh D.

Am J Health Syst Pharm. 2013 Dec 1;70(23):2137-42. doi: 10.2146/ajhp120372.

PMID:
24249764

Supplemental Content

Loading ...
Support Center